Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
N-115 by EmphyCorp for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
N-115 is under clinical development by EmphyCorp and currently in Pre-Registration for Idiopathic Pulmonary Fibrosis. According to GlobalData, Pre-Registration drugs...
N-115 by EmphyCorp for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
N-115 is under clinical development by EmphyCorp and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData,...
N-115 by EmphyCorp for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
N-115 is under clinical development by EmphyCorp and currently in Phase III for Post-Acute Sequelae of COVID 2019 (PASC or...
N-115 by EmphyCorp for Allergic Rhinitis: Likelihood of Approval
N-115 is under clinical development by EmphyCorp and currently in Phase II for Allergic Rhinitis. According to GlobalData, Phase II...